Elaine Haynes is the President and Chief Executive Officer of KaloCyte, where she oversees the company’s business operations and drives execution on ErythroMer’s technical development and grant funding strategies. Ms. Haynes is a seasoned and resilient executive with over 30 years of healthcare leadership expertise and extensive experience with commercial development of complex pharmaceuticals.